Adapting to obesity with adipose tissue inflammation

Key Points

  • Adipocytes have an important role in sensing and managing energy status

  • Adipose tissue responds to overnutrition by mounting an immune response; however, the initial inflammatory trigger in adipose tissue is unknown

  • Inflammation induces insulin resistance through a variety of molecular mechanisms

  • The maladaptive responses that occur in long-term obesity are a result of chronic inflammation, particularly catecholamine resistance

  • Inflammatory pathways are intriguing therapeutic targets for metabolic disease; however, the clinical efficacy of drugs targeting these pathways has been disappointing


Adipose tissue not only has an important role in the storage of excess nutrients but also senses nutrient status and regulates energy mobilization. An overall positive energy balance is associated with overnutrition and leads to excessive accumulation of fat in adipocytes. These cells respond by initiating an inflammatory response that, although maladaptive in the long run, might initially be a physiological response to the stresses obesity places on adipose tissue. In this Review, we characterize adipose tissue inflammation and review the current knowledge of what triggers obesity-associated inflammation in adipose tissue. We examine the connection between adipose tissue inflammation and the development of insulin resistance and catecholamine resistance and discuss the ensuing state of metabolic inflexibility. Finally, we review the current and potential new anti-inflammatory treatments for obesity-associated metabolic disease.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Adaptive and maladaptive phases of inflammation in metabolic disease.
Figure 2: Initiators of obesity-associated inflammation in adipocytes.
Figure 3: Mechanisms underlying obesity-associated catecholamine resistance.


  1. 1

    Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860–867 (2006).

  2. 2

    Lumeng, C. N. & Saltiel, A. R. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121, 2111–2117 (2011).

  3. 3

    Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219–246 (2010).

  4. 4

    Kotas, M. E. & Medzhitov, R. Homeostasis, inflammation, and disease susceptibility. Cell 160, 816–827 (2015).

  5. 5

    Buettner, C. et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat. Med. 14, 667–675 (2008).

  6. 6

    Scarpace, P. J. & Matheny, M. Leptin induction of UCP1 gene expression is dependent on sympathetic innervation. Am. J. Physiol. 275, E259–E264 (1998).

  7. 7

    Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994).

  8. 8

    Frederich, R. C. et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat. Med. 1, 1311–1314 (1995).

  9. 9

    Considine, R. V. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334, 292–295 (1996).

  10. 10

    Shen, J., Tanida, M., Niijima, A. & Nagai, K. In vivo effects of leptin on autonomic nerve activity and lipolysis in rats. Neurosci. Lett. 416, 193–197 (2007).

  11. 11

    Friedman, J. M. Obesity in the new millennium. Nature 404, 632–634 (2000).

  12. 12

    Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799–806 (2001).

  13. 13

    Fisher, F. M. et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26, 271–281 (2012).

  14. 14

    Emanuelli, B. et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J. Clin. Invest. 124, 515–527 (2014).

  15. 15

    Hondares, E. et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J. Biol. Chem. 286, 12983–12990 (2011).

  16. 16

    Yamauchi, T. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762–769 (2003).

  17. 17

    Trujillo, M. E. & Scherer, P. E. Adiponectin — journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med. 257, 167–175 (2005).

  18. 18

    Fruebis, J. et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci. USA 98, 2005–2010 (2001).

  19. 19

    Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941–946 (2001).

  20. 20

    Berg, A. H., Combs, T. P., Du, X., Brownlee, M. & Scherer, P. E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7, 947–953 (2001).

  21. 21

    Mora, S. & Pessin, J. E. An adipocentric view of signaling and intracellular trafficking. Diabetes Metab. Res. Rev. 18, 345–356 (2002).

  22. 22

    Lidell, M. E. et al. Evidence for two types of brown adipose tissue in humans. Nat. Med. 19, 631–634 (2013).

  23. 23

    Tews, D. et al. Comparative gene array analysis of progenitor cells from human paired deep neck and subcutaneous adipose tissue. Mol. Cell. Endocrinol. 395, 41–50 (2014).

  24. 24

    Wu, J. et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150, 366–376 (2012).

  25. 25

    Hu, H. H. et al. MRI detection of brown adipose tissue with low fat content in newborns with hypothermia. Magn. Reson. Imaging 32, 107–117 (2014).

  26. 26

    Young, P., Arch, J. R. & Ashwell, M. Brown adipose tissue in the parametrial fat pad of the mouse. FEBS Lett. 167, 10–14 (1984).

  27. 27

    Liu, W. et al. A heterogeneous lineage origin underlies the phenotypic and molecular differences of white and beige adipocytes. J. Cell Sci. 126, 3527–3532 (2013).

  28. 28

    Wang, W. & Seale, P. Control of brown and beige fat development. Nat. Rev. Mol. Cell Biol. 17, 691–702 (2016).

  29. 29

    Sidossis, L. & Kajimura, S. Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. J. Clin. Invest. 125, 478–486 (2015).

  30. 30

    Brestoff, J. R. & Artis, D. Immune regulation of metabolic homeostasis in health and disease. Cell 161, 146–160 (2015).

  31. 31

    Harms, M. & Seale, P. Brown and beige fat: development, function and therapeutic potential. Nat. Med. 19, 1252–1263 (2013).

  32. 32

    Lizcano, F. & Vargas, D. Biology of beige adipocyte and possible therapy for type 2 diabetes and obesity. Int. J. Endocrinol. 2016, 9542061 (2016).

  33. 33

    van den Berg, S. M., van Dam, A. D., Rensen, P. C., de Winther, M. P. & Lutgens, E. Immune modulation of brown(ing) adipose tissue in obesity. Endocr. Rev. 38, 46–68 (2017).

  34. 34

    Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–1481 (2008).

  35. 35

    Saad, M. J., Santos, A. & Prada, P. O. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology (Bethesda) 31, 283–293 (2016).

  36. 36

    Kim, J. Y. et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117, 2621–2637 (2007).

  37. 37

    Wernstedt Asterholm, I. et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 20, 103–118 (2014).

  38. 38

    Jayashree, B. et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol. Cell. Biochem. 388, 203–210 (2014).

  39. 39

    Nguyen, M. T. et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282, 35279–35292 (2007).

  40. 40

    Lee, J. Y. et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J. Biol. Chem. 279, 16971–16979 (2004).

  41. 41

    Ghanim, H. et al. Acute modulation of Toll-like receptors by insulin. Diabetes Care 31, 1827–1831 (2008).

  42. 42

    Vitseva, O. I. et al. Inducible Toll-like receptor and NF-kappaB regulatory pathway expression in human adipose tissue. Obesity (Silver Spring) 16, 932–937 (2008).

  43. 43

    Makowski, L., Brittingham, K. C., Reynolds, J. M., Suttles, J. & Hotamisligil, G. S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J. Biol. Chem. 280, 12888–12895 (2005).

  44. 44

    Cranmer-Byng, M. M., Liddle, D. M., De Boer, A. A., Monk, J. M. & Robinson, L. E. Proinflammatory effects of arachidonic acid in a lipopolysaccharide-induced inflammatory microenvironment in 3T3-L1 adipocytes in vitro. Appl. Physiol. Nutr. Metab. 40, 142–154 (2015).

  45. 45

    Rocha, D. M., Bressan, J. & Hermsdorff, H. H. The role of dietary fatty acid intake in inflammatory gene expression: a critical review. Sao Paulo Med. J. 135, 157–168 (2017).

  46. 46

    Chilton, L. et al. Metabolism of gammalinolenic acid in human neutrophils. J. Immunol. 156, 2941–2947 (1996).

  47. 47

    Simopoulos, A. P. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients 8, 128 (2016).

  48. 48

    Khan, S. A. et al. Unraveling the complex relationship triad between lipids, obesity, and inflammation. Mediators Inflamm. 2014, 502749 (2014).

  49. 49

    Oliveira, V. et al. Diets containing alpha-linolenic (omega3) or oleic (omega9) fatty acids rescues obese mice from insulin resistance. Endocrinology 156, 4033–4046 (2015).

  50. 50

    Finucane, O. M. et al. Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1beta secretion and insulin resistance despite obesity. Diabetes 64, 2116–2128 (2015).

  51. 51

    Scoditti, E. et al. Additive regulation of adiponectin expression by the mediterranean diet olive oil components oleic acid and hydroxytyrosol in human adipocytes. PLoS ONE 10, e0128218 (2015).

  52. 52

    Estruch, R. et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 368, 1279–1290 (2013).

  53. 53

    Cinti, S. et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46, 2347–2355 (2005).

  54. 54

    Fischer-Posovszky, P., Wang, Q. A., Asterholm, I. W., Rutkowski, J. M. & Scherer, P. E. Targeted deletion of adipocytes by apoptosis leads to adipose tissue recruitment of alternatively activated M2 macrophages. Endocrinology 152, 3074–3081 (2011).

  55. 55

    Strissel, K. J. et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 56, 2910–2918 (2007).

  56. 56

    Lumeng, C. N., Deyoung, S. M., Bodzin, J. L. & Saltiel, A. R. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56, 16–23 (2007).

  57. 57

    Haase, J. et al. Local proliferation of macrophages in adipose tissue during obesity-induced inflammation. Diabetologia 57, 562–571 (2014).

  58. 58

    Jin, C. & Flavell, R. A. Innate sensors of pathogen and stress: linking inflammation to obesity. J. Allergy Clin. Immunol. 132, 287–294 (2013).

  59. 59

    Shi, Y., Evans, J. E. & Rock, K. L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516–521 (2003).

  60. 60

    Lamkanfi, M. & Dixit, V. M. Inflammasomes: guardians of cytosolic sanctity. Immunol. Rev. 227, 95–105 (2009).

  61. 61

    Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188 (2011).

  62. 62

    Schroder, K., Zhou, R. & Tschopp, J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 327, 296–300 (2010).

  63. 63

    Lee, Y. S. et al. Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity. Cell 157, 1339–1352 (2014).

  64. 64

    Gonzalez-Muniesa, P. et al. Effects of hyperoxia on oxygen-related inflammation with a focus on obesity. Oxid. Med. Cell. Longev. 2015, 8957827 (2015).

  65. 65

    Ye, J., Gao, Z., Yin, J. & He, Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. 293, E1118–E1128 (2007).

  66. 66

    Quintero, P., Gonzalez-Muniesa, P., Garcia-Diaz, D. F. & Martinez, J. A. Effects of hyperoxia exposure on metabolic markers and gene expression in 3T3-L1 adipocytes. J. Physiol. Biochem. 68, 663–669 (2012).

  67. 67

    Trayhurn, P., Wang, B. & Wood, I. S. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br. J. Nutr. 100, 227–235 (2008).

  68. 68

    He, Q. et al. Regulation of HIF-1α activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia. Am. J. Physiol. Endocrinol. Metab. 300, E877–E885 (2011).

  69. 69

    Trayhurn, P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol. Rev. 93, 1–21 (2013).

  70. 70

    Rausch, M. E., Weisberg, S., Vardhana, P. & Tortoriello, D. V. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int. J. Obes. (Lond.) 32, 451–463 (2008).

  71. 71

    Rius, J. et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453, 807–811 (2008).

  72. 72

    Skinner, B. M. & Johnson, E. E. Nuclear morphologies: their diversity and functional relevance. Chromosoma 126, 195–212 (2017).

  73. 73

    Williams, A. S., Kang, L. & Wasserman, D. H. The extracellular matrix and insulin resistance. Trends Endocrinol. Metab. 26, 357–366 (2015).

  74. 74

    Khan, T. et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol. Cell. Biol. 29, 1575–1591 (2009).

  75. 75

    Chun, T. H. et al. A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell 125, 577–591 (2006).

  76. 76

    McBeath, R., Pirone, D. M., Nelson, C. M., Bhadriraju, K. & Chen, C. S. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev. Cell 6, 483–495 (2004).

  77. 77

    Hara, Y. et al. Rho and Rho-kinase activity in adipocytes contributes to a vicious cycle in obesity that may involve mechanical stretch. Sci. Signal. 4, ra3 (2011).

  78. 78

    Li, Q., Hata, A., Kosugi, C., Kataoka, N. & Funaki, M. The density of extracellular matrix proteins regulates inflammation and insulin signaling in adipocytes. FEBS Lett. 584, 4145–4150 (2010).

  79. 79

    Doherty, T. A. At the bench: understanding group 2 innate lymphoid cells in disease. J. Leukoc. Biol. 97, 455–467 (2015).

  80. 80

    Moro, K. et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. Nature 463, 540–544 (2010).

  81. 81

    Molofsky, A. B. et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J. Exp. Med. 210, 535–549 (2013).

  82. 82

    Lee, M. W. et al. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell 160, 74–87 (2015).

  83. 83

    Brestoff, J. R. et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519, 242–246 (2015).

  84. 84

    Odegaard, J. I. et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 1116–1120 (2007).

  85. 85

    Kang, K. et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 7, 485–495 (2008).

  86. 86

    Fujisaka, S. et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 58, 2574–2582 (2009).

  87. 87

    Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808 (2003).

  88. 88

    Lackey, D. E. & Olefsky, J. M. Regulation of metabolism by the innate immune system. Nat. Rev. Endocrinol. 12, 15–28 (2016).

  89. 89

    Xu, X. et al. Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation. Cell Metab. 18, 816–830 (2013).

  90. 90

    Kratz, M. et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab. 20, 614–625 (2014).

  91. 91

    Odegaard, J. I. et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 7, 496–507 (2008).

  92. 92

    McLaughlin, T. et al. T-Cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler. Thromb. Vasc. Biol. 34, 2637–2643 (2014).

  93. 93

    Nishimura, S. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15, 914–920 (2009).

  94. 94

    Yang, H. et al. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J. Immunol. 185, 1836–1845 (2010).

  95. 95

    Travers, R. L., Motta, A. C., Betts, J. A., Bouloumie, A. & Thompson, D. The impact of adiposity on adipose tissue-resident lymphocyte activation in humans. Int. J. Obes. (Lond.) 39, 762–769 (2015).

  96. 96

    Winer, S. et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 15, 921–929 (2009).

  97. 97

    Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930–939 (2009).

  98. 98

    Bapat, S. P. et al. Depletion of fat-resident Treg cells prevents age-associated insulin resistance. Nature 528, 137–141 (2015).

  99. 99

    Duffaut, C., Galitzky, J., Lafontan, M. & Bouloumie, A. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem. Biophys. Res. Commun. 384, 482–485 (2009).

  100. 100

    Kitamura, D., Roes, J., Kuhn, R. & Rajewsky, K. A. B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350, 423–426 (1991).

  101. 101

    Winer, D. A. et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 17, 610–617 (2011).

  102. 102

    DeFuria, J. et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc. Natl Acad. Sci. USA 110, 5133–5138 (2013).

  103. 103

    Shen, L. et al. B-1a lymphocytes attenuate insulin resistance. Diabetes 64, 593–603 (2015).

  104. 104

    Deng, T. et al. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab. 17, 411–422 (2013).

  105. 105

    Huh, J. Y. et al. Deletion of CD1d in adipocytes aggravates adipose tissue inflammation and insulin resistance in obesity. Diabetes 66, 835–847 (2017).

  106. 106

    Schmitz, J. et al. Obesogenic memory can confer long-term increases in adipose tissue but not liver inflammation and insulin resistance after weight loss. Mol. Metab. 5, 328–339 (2016).

  107. 107

    Mayoral Monibas, R., Johnson, A. M., Osborn, O., Traves, P. G. & Mahata, S. K. Distinct hepatic macrophage populations in lean and obese mice. Front. Endocrinol. (Lausanne) 7, 152 (2016).

  108. 108

    Winer, D. A., Luck, H., Tsai, S. & Winer, S. The intestinal immune system in obesity and insulin resistance. Cell Metab. 23, 413–426 (2016).

  109. 109

    Yu, E. et al. Weight history and all-cause and cause-specific mortality in three prospective cohort studies. Ann. Intern. Med. 166, 613–620 (2017).

  110. 110

    Hardy, O. T. et al. Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity. Surg. Obes. Relat. Dis. 7, 60–67 (2011).

  111. 111

    Kloting, N. et al. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299, E506–E515 (2010).

  112. 112

    Arkan, M. C. et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191–198 (2005).

  113. 113

    Hirosumi, J. et al. A central role for JNK in obesity and insulin resistance. Nature 420, 333–336 (2002).

  114. 114

    Holland, W. L. et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5, 167–179 (2007).

  115. 115

    Shi, H. et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116, 3015–3025 (2006).

  116. 116

    Nakamura, T. et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 140, 338–348 (2010).

  117. 117

    Hotamisligil, G. S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900–917 (2010).

  118. 118

    Summers, S. A. Sphingolipids and insulin resistance: the five Ws. Curr. Opin. Lipidol. 21, 128–135 (2010).

  119. 119

    Saberi, M. et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 10, 419–429 (2009).

  120. 120

    Wellen, K. E. et al. Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell 129, 537–548 (2007).

  121. 121

    Lesniewski, L. A. et al. Bone marrow-specific Cap gene deletion protects against high-fat diet-induced insulin resistance. Nat. Med. 13, 455–462 (2007).

  122. 122

    Li, P. et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat. Med. 21, 239–247 (2015).

  123. 123

    Li, P. et al. Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance. Cell 167, 973–984.e12 (2016).

  124. 124

    Himes, R. W. & Smith, C. W. Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J. 24, 731–739 (2010).

  125. 125

    Avota, E., Gulbins, E. & Schneider-Schaulies, S. DC-SIGN mediated sphingomyelinase-activation and ceramide generation is essential for enhancement of viral uptake in dendritic cells. PLoS Pathog. 7, e1001290 (2011).

  126. 126

    Summers, S. A., Garza, L. A., Zhou, H. & Birnbaum, M. J. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol. Cell. Biol. 18, 5457–5464 (1998).

  127. 127

    Teruel, T., Hernandez, R. & Lorenzo, M. Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 50, 2563–2571 (2001).

  128. 128

    Stratford, S., Hoehn, K. L., Liu, F. & Summers, S. A. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol. Chem. 279, 36608–36615 (2004).

  129. 129

    Solinas, G. et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 6, 386–397 (2007).

  130. 130

    Witczak, C. A. et al. JNK1 deficiency does not enhance muscle glucose metabolism in lean mice. Biochem. Biophys. Res. Commun. 350, 1063–1068 (2006).

  131. 131

    Chiang, S. H. et al. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell 138, 961–975 (2009).

  132. 132

    Baker, R. G., Hayden, M. S. & Ghosh, S. NF-kappaB, inflammation, and metabolic disease. Cell Metab. 13, 11–22 (2011).

  133. 133

    Zick, Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci. STKE 2005, pe4 (2005).

  134. 134

    Arner, P., Arner, E., Hammarstedt, A. & Smith, U. Genetic predisposition for type 2 diabetes, but not for overweight/obesity, is associated with a restricted adipogenesis. PLoS ONE 6, e18284 (2011).

  135. 135

    Tchkonia, T. et al. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab. 17, 644–656 (2013).

  136. 136

    Chung, S. et al. Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology 147, 5340–5351 (2006).

  137. 137

    Saltiel, A. R. Insulin resistance in the defense against obesity. Cell Metab. 15, 798–804 (2012).

  138. 138

    Lu, Q., Li, M., Zou, Y. & Cao, T. Induction of adipocyte hyperplasia in subcutaneous fat depot alleviated type 2 diabetes symptoms in obese mice. Obesity (Silver Spring) 22, 1623–1631 (2014).

  139. 139

    Nov, O. et al. Interleukin-1beta regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. PLoS ONE 8, e53626 (2013).

  140. 140

    Arner, P. Catecholamine-induced lipolysis in obesity. Int. J. Obes. Relat. Metab. Disord. 23 (Suppl. 1), 10–13 (1999).

  141. 141

    Knight, Z. A., Hannan, K. S., Greenberg, M. L. & Friedman, J. M. Hyperleptinemia is required for the development of leptin resistance. PLoS ONE 5, e11376 (2010).

  142. 142

    Caro, J. F. et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 348, 159–161 (1996).

  143. 143

    Diano, S., Kalra, S. P. & Horvath, T. L. Leptin receptor immunoreactivity is associated with the Golgi apparatus of hypothalamic neurons and glial cells. J. Neuroendocrinol. 10, 647–650 (1998).

  144. 144

    Ozcan, L. et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 9, 35–51 (2009).

  145. 145

    Zhang, X. et al. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell 135, 61–73 (2008).

  146. 146

    Collins, S., Daniel, K. W., Petro, A. E. & Surwit, R. S. Strain-specific response to beta 3-adrenergic receptor agonist treatment of diet-induced obesity in mice. Endocrinology 138, 405–413 (1997).

  147. 147

    Gettys, T. W. et al. Age-dependent changes in beta-adrenergic receptor subtypes and adenylyl cyclase activation in adipocytes from Fischer 344 rats. Endocrinology 136, 2022–2032 (1995).

  148. 148

    Bougneres, P. et al. In vivo resistance of lipolysis to epinephrine. A new feature of childhood onset obesity. J. Clin. Invest. 99, 2568–2573 (1997).

  149. 149

    Reynisdottir, S., Ellerfeldt, K., Wahrenberg, H., Lithell, H. & Arner, P. Multiple lipolysis defects in the insulin resistance (metabolic) syndrome. J. Clin. Invest. 93, 2590–2599 (1994).

  150. 150

    Horowitz, J. F. & Klein, S. Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper body obese women. Am. J. Physiol. Endocrinol. Metab. 278, E1144–E1152 (2000).

  151. 151

    Lowell, B. B. & Bachman, E. S. Beta-adrenergic receptors, diet-induced thermogenesis, and obesity. J. Biol. Chem. 278, 29385–29388 (2003).

  152. 152

    Sakamoto, T. et al. Macrophage infiltration into obese adipose tissues suppresses the induction of UCP1 level in mice. Am. J. Physiol. Endocrinol. Metab. 310, E676–E687 (2016).

  153. 153

    Guo, T. et al. Adipocyte ALK7 links nutrient overload to catecholamine resistance in obesity. eLife 3, e03245 (2014).

  154. 154

    Mowers, J. et al. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1. eLife 2, e01119 (2013).

  155. 155

    Reilly, S. M. et al. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat. Med. 19, 313–321 (2013).

  156. 156

    Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2, 364–371 (2002).

  157. 157

    Ofei, F., Hurel, S., Newkirk, J., Sopwith, M. & Taylor, R. Effects of an engineered human anti-TNFa antibody (SDP571) on insulin sensitivity and glycemic control in pateints with NIDDM. Diabetes 45, 881–885 (1996).

  158. 158

    Solomon, D. H. et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 305, 2525–2531 (2011).

  159. 159

    Moller, D. E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab. 11, 212–217 (2000).

  160. 160

    Ofei, F., Hurel, S., Newkirk, J., Sopwith, M. & Taylor, R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45, 881–885 (1996).

  161. 161

    Sloan-Lancaster, J. et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239–2246 (2013).

  162. 162

    Goldfine, A. B. et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 152, 346–357 (2010).

  163. 163

    Hawley, S. A. et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336, 918–922 (2012).

  164. 164

    Goldfine, A. B. et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 56, 714–723 (2013).

  165. 165

    Penesova, A. et al. Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo-controlled trial in subjects without diabetes. Diabetes Obes. Metab. 17, 608–612 (2015).

  166. 166

    Cipolletta, D. et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486, 549–553 (2012).

  167. 167

    Reilly, S. M. et al. A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis. Nat. Commun. 6, 6047 (2015).

  168. 168

    Oral, E. A. et al. Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes. Cell Metab. 26 157–170 (2017).

  169. 169

    Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3, e02242 (2014).

  170. 170

    Isoda, K. et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 26, 611–617 (2006).

  171. 171

    Koppaka, S. et al. Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans. Diabetes 62, 1843–1854 (2013).

  172. 172

    Peraldi, P., Xu, M. & Spiegelman, B. M. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J. Clin. Invest. 100, 1863–1869 (1997).

  173. 173

    Chawla, A. Control of macrophage activation and function by PPARs. Circ. Res. 106, 1559–1569 (2010).

  174. 174

    Kirwan, J. P. et al. TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes 51, 2207–2213 (2002).

  175. 175

    Ategbo, J. M. et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J. Clin. Endocrinol. Metab. 91, 4137–4143 (2006).

  176. 176

    Xu, J. et al. Maternal circulating concentrations of tumor necrosis factor-alpha, leptin, and adiponectin in gestational diabetes mellitus: a systematic review and meta-analysis. ScientificWorldJournal 2014, 926932 (2014).

Download references

Author information

S.M.R. and A.R.S. researched data for the article, contributed to discussion of the content, wrote the article and reviewed and/or edited the article before submission.

Correspondence to Alan R. Saltiel.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides


Biogenic amines

Endogenous molecules with one or more amine groups; five important neurotransmitters are biogenic amines, including three catecholamines (dopamine, noradrenaline and adrenaline) as well as histamine and serotonin.

Mesenteric adipose tissue

A small membrane-like visceral fat depot connected to the intestine that expands into a large adipose depot surrounding the intestine during obesity.

Crown-like structures

These histological structures are observed in adipose tissue and are the result of immune cells surrounding dead adipocytes; as the immune cells pack into the spaces around the dead adipocytes and between the surrounding live adipocytes, they form a shape reminiscent of a crown.

Oxygen tension

The partial pressure of oxygen within a tissue, which is a measure of the amount of oxygen within the tissue.


The differentiation of pre-adipocytes (or other fibroblast-like cells) to make new adipocytes.

Type 2 or T helper 2 (TH2)

Type 2 cytokines, such as IL-4 and IL-13, are classified based on their secretion from TH2 cells (however, they are secreted from many other immune cells) and are typically anti-inflammatory and promote M2 macrophage differentiation; type 2 immunity is characterized by antibody-mediated immune responses.

Type 1 or T helper 1 (TH1)

Type 1 cytokines, such as IL-1β and tumour necrosis factor, are classified based on their secretion from TH1 cells (however, they are secreted from many other immune cells) and are typically pro-inflammatory; type 1 immunity is characterized by a phagocytic immune response.


The proliferation and migration of endothelial cells to form new blood vessels.

Metabolic inflexibility

A state in which responsiveness to catabolic and anabolic signals is reduced in adipocytes, leaving them unable to efficiently contract (mobilize nutrients) or expand (store nutrients).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Reilly, S., Saltiel, A. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol 13, 633–643 (2017).

Download citation

Further reading